Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126100
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Miró Meda, José M. | - |
dc.contributor.author | HIV Study Group investigators | - |
dc.date.accessioned | 2018-11-14T12:28:42Z | - |
dc.date.available | 2018-11-14T12:28:42Z | - |
dc.date.issued | 2017-01-28 | - |
dc.identifier.issn | 0269-9370 | - |
dc.identifier.uri | http://hdl.handle.net/2445/126100 | - |
dc.description.abstract | OBJECTIVES: The high mortality among HIV/tuberculosis (TB) coinfected patients in Eastern Europe is partly explained by the high prevalence of drug-resistant TB. It remains unclear whether outcomes of HIV/TB patients with rifampicin/isoniazid-susceptible TB in Eastern Europe differ from those in Western Europe or Latin America. METHODS: One-year mortality of HIV-positive patients with rifampicin/isoniazid-susceptible TB in Eastern Europe, Western Europe, and Latin America was analysed and compared in a prospective observational cohort study. Factors associated with death were analysed using Cox regression modelsRESULTS:: Three hundred and forty-one patients were included (Eastern Europe 127, Western Europe 165, Latin America 49). Proportions of patients with disseminated TB (50, 58, 59%) and initiating rifampicin + isoniazid + pyrazinamide-based treatment (93, 94, 94%) were similar in Eastern Europe, Western Europe, and Latin America respectively, whereas receipt of antiretroviral therapy at baseline and after 12 months was lower in Eastern Europe (17, 39, 39%, and 69, 94, 89%). The 1-year probability of death was 16% (95% confidence interval 11-24%) in Eastern Europe, vs. 4% (2-9%) in Western Europe and 9% (3-21%) in Latin America; P < 0.0001. After adjustment for IDU, CD4 cell count and receipt of antiretroviral therapy, those residing in Eastern Europe were at nearly 3-fold increased risk of death compared with those in Western Europe/Latin America (aHR 2.79 (1.15-6.76); P = 0.023). CONCLUSIONS: Despite comparable use of recommended anti-TB treatment, mortality of patients with rifampicin/isoniazid-susceptible TB remained higher in Eastern Europe when compared with Western Europe/Latin America. The high mortality in Eastern Europe was only partially explained by IDU, use of ART and CD4 cell count. These results call for improvement of care for TB/HIV patients in Eastern Europe. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Lippincott, Williams & Wilkins | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1097/QAD.0000000000001333 | - |
dc.relation.ispartof | AIDS, 2017, vol. 31, num. 3, p. 375-384 | - |
dc.relation.uri | https://doi.org/10.1097/QAD.0000000000001333 | - |
dc.rights | (c) Lippincott, Williams & Wilkins, 2017 | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Persones seropositives | - |
dc.subject.classification | Mortalitat | - |
dc.subject.classification | Tuberculosi | - |
dc.subject.other | HIV-positive persons | - |
dc.subject.other | Mortality | - |
dc.subject.other | Tuberculosis | - |
dc.title | One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 669009 | - |
dc.date.updated | 2018-11-14T12:28:42Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28081036 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
669009.pdf | 300.19 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.